About Martin and Harris Unlisted Shares
Founded in 1996, Martin & Harris Laboratories Ltd, based in Gurgaon, Haryana, is a key player in India’s pharmaceutical industry. The company is part of the prestigious Apeejay Group, one of the oldest and largest business conglomerates in India. Mrs. Sushma Paul Berlia, one of the co-promoters and president of Apeejay Stya & Svran Group, plays a pivotal role in the company’s success. Martin & Harris specializes in manufacturing pharmaceutical products, medicinal chemicals, and botanical products, with a keen focus on quality and innovation. In addition to its core pharmaceutical business, the company also actively invests in various sectors, such as mutual funds and equities, generating substantial returns.
Business Divisions
Martin & Harris Laboratories Ltd operates through two primary business verticals:
- Pharmaceutical Business (52% of Revenue): The company manufactures a wide range of pharmaceutical products, ensuring that all its offerings meet international quality standards. These products cater to diverse therapeutic segments, contributing to a strong market presence in the domestic and international markets.
- Derivative and Investment Business (48% of Revenue): Alongside its pharmaceutical operations, Martin & Harris has built a robust investment portfolio, consisting of mutual funds, equity investments (both quoted and unquoted), and other avenues that provide attractive returns. This business division helps balance risks and creates additional revenue streams for the company.
Martin & Harris is constantly enhancing its manufacturing units located in Roorkee (Uttarakhand) and UNA (Himachal Pradesh) to meet the ever-evolving needs of the global pharmaceutical market.
Financial Highlights
Here are the key financial highlights for Martin & Harris Laboratories Ltd that reflect its strong performance and growth potential, especially for those considering Martin and Harris Unlisted Shares:
- Revenue Growth: Martin & Harris recorded a revenue of ₹146 million in its most recent fiscal year. Although this represents a slight decline from ₹205 million in the previous year, it continues to maintain steady revenue generation across both business divisions.
- Strong Gross Margins: The company has consistently maintained high gross margins, which stood at 71.92% in the most recent year. This is an improvement from 73.12% in the prior year, indicating effective cost management and a solid product portfolio.
- EBITDA and Profitability: The company’s EBITDA was ₹26 million, showcasing a solid operational performance, although it slightly declined from ₹72 million the previous year. The decline in EBITDA can be attributed to higher operating expenses but still reflects healthy profitability.
- Net Profit Growth: Martin & Harris recorded a net profit of ₹40 million with a notable profit margin of 27.4%. This reflects an overall healthy business structure despite challenges in certain segments, with the company maintaining consistent profitability across its pharmaceutical and investment divisions.
- Earnings Per Share (EPS): The company’s EPS was ₹100.25, a good indicator of profitability and value for investors. Given its relatively low P/E ratio of 8.49, Martin & Harris represents an attractive investment opportunity, especially when compared to other players in the pharmaceutical sector.
